-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Jiuzhitang (000989.SZ) issued an announcement that the company's shareholding company, Beijing KexinMeide Biomedical Technology Co., Ltd. (“KexinMide”) and its affiliate, Remd Biotherapeutics Inc. (REMD Biotherapeutics Inc.), a Class 1 innovative antibody drug targeting glucagon receptors, has recently obtained the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration. REMD-477 It was agreed to conduct clinical trials of this product in Chinese type 1 diabetes (T1DM) patients.
Share
Listen to the news
Zhitong Finance App News, Jiuzhitang (000989.SZ) issued an announcement that the company's shareholding company, Beijing KexinMeide Biomedical Technology Co., Ltd. (“KexinMide”) and its affiliate, Remd Biotherapeutics Inc. (REMD Biotherapeutics Inc.), a Class 1 innovative antibody drug targeting glucagon receptors, has recently obtained the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration. REMD-477 It was agreed to conduct clinical trials of this product in Chinese type 1 diabetes (T1DM) patients.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending